Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune, Autoinflammatory & Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IFN-gamma drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IFNG Recombinant Protein (Wild-Type & Mutant Panel) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli or HEK293 expressed. |
View IFNG Products |
| Receptor | IFNGR1/IFNGR2 ECD-Fc Fusion Proteins Human/Mouse/Cyno orthologs for binding assays. |
View IFNGR1 Products |
| Gene Delivery | IFNG Promise-ORF / Lentivirus Full-length ORF for overexpression or stable cell line studies. |
View IFNG Products |
| Benchmark Ab | Anti-IFNG Neutralizing Antibody (Sequence of Emapalumab, additional reference: Fontolizumab) Recombinant positive control for blocking assays. |
View IFNG Products |
| Validator | IFNG siRNA Set For knockdown verification. |
View IFNG Products |
| Related Target: IFNGR2 | Interferon Gamma Receptor 2 Beta chain signaling component; essential for JAK-STAT pathway activation. |
View IFNGR2 Products |
| Related Target: IL-12 | Interleukin-12 Upstream inducer of IFN-gamma; synergistic pathway for combination therapy screening. |
View IL-12 Products |
| Related Target: TNF-alpha | Tumor Necrosis Factor Alpha Synergistic cytokine; combination blockade candidate for autoimmune indications. |
View TNF Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval | Human/Mouse/Cyno IFNG and IFNGR1 ortholog proteins available with >95% purity; Sequence Verified by Mass Spec |
| IFN family selectivity screening | Homolog panel including IFN-alpha, IFN-beta, IFN-lambda strictly verified by mass spec for off-target binding assays |
| Receptor complex binding validation | Heterodimeric IFNGR1/IFNGR2 co-expression lysates available for native conformation studies |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization |
| False Positives | Validated siRNA included for specificity checks in cellular assays |
Live IFNG R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IFN-gamma therapeutics is intensifying, with major players shifting focus from broad immunosuppression to targeted pathway modulation. As first-generation anti-IFN therapies face patent cliffs, the next wave of R&D is targeting pH-dependent binding antibodies for extended half-life and subcutaneous delivery formats. However, because IFN-gamma sits at the apex of Th1 immunity, complete signal blockade carries inherent safety constraints, including risk of opportunistic infections and impaired tumor surveillance. This limits indication expansion primarily to acute, life-threatening hyperinflammatory states such as hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), systemic juvenile idiopathic arthritis (sJIA), and checkpoint-inhibitor-related cytokine release syndromes. Consequently, best-in-class candidates must demonstrate superior neutralizing potency, a clean counter-screen against Type I interferons, and robust cross-reactivity to cynomolgus monkey for toxicology studies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing Antibody | Novartis, Roche, AbbVie, Sobi (Emapalumab) | Autoimmune (RA, MS, IBD), HLH, MAS | High-affinity binding assay (Need purified IFNG & IFNGR1) |
| Fusion Protein | Biogen, Bristol Myers Squibb | Immunology | Stability assay (Need Endotoxin-controlled <1EU/ug) |
| Recombinant Agonist | Merck, AstraZeneca, Horizon (Actimmune) | Immuno-Oncology, Chronic Granulomatous Disease | Bioactivity reporter assay (Need Sequence-verified protein) |
| Small Molecule | Incyte, Eli Lilly | Refractory Autoimmune | Receptor competition assay (Need IFNGR1/IFNGR2 heterodimer) |
| High-Concentration Subcutaneous mAb | Novartis, Roche (next-gen focus) | Chronic Autoinflammation | Viscosity/stability screen (Need aggregation-free antigen) |
| Combination Cytokine Blockade | Various (IL-1/IL-6 synergy) | Refractory Cytokine Storm (HLH, MAS, CRS) | Panel specificity (Need human cytokine homolog panel) |